R&D News | pharmaphorum

News

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

News

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the

News

Elizabeth Holmes heading for prison as appeal fails

Disgraced former biotech chief Elizabeth Holmes will start an 11-year prison sentence at the end of this month, after a federal judge denied her request to remain free whi

News

Moderna’s flu vaccine trial delayed by case numbers

Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

News

Merck gets stuck on Proxygen’s molecular glue degraders

Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Elizabeth Holmes heading for prison as appeal fails

Moderna’s flu vaccine trial delayed by case numbers

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Merck gets stuck on Proxygen’s molecular glue degraders

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks